<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995472</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1501-I-101</org_study_id>
    <nct_id>NCT03995472</nct_id>
  </id_info>
  <brief_title>A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors</brief_title>
  <official_title>A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in
      combination with SHR-1316 in patients with advanced malignancies and to provide a recommended
      dose (RP2D) for subsequent clinical studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity and Maximum tolerated dose</measure>
    <time_frame>Approximately 42 Days.</time_frame>
    <description>Dose-limiting toxicity and Maximum tolerated dose in patients with advanced tumors treated by SHR-1501 combined with SHR-1316.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Recommended Phase 2 dose (RP2D) based on comprehensive evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event/Serious adverse event</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Incidence/severity of adverse events/serious adverse events (rated based on CTC AE v5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Single dose: maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Single dose: time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Single dose: areas under the concentration-time curve (AUClast and AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Single dose: half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Single dose: clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Single dose: mean residence time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Single dose: volume at steady state (Vss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Multiple doses (at steady state, if applicable): maximum concentration at steady state （Css_max）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Multiple doses (at steady state, if applicable): time to maximum concentration （Tss_max）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Multiple doses (at steady state, if applicable): area under the concentration-time curve at steady state （AUCss）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Multiple doses (at steady state, if applicable): t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Multiple doses (at steady state, if applicable):steady-state minimum concentration at steady state （Css_min）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Multiple doses (at steady state, if applicable): average concentration at steady state（Css_av）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Multiple doses (at steady state, if applicable): accumulation ratio （Rac）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune related features</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>indicated by the count of CD8+ T-lymphocytes in peripheral blood at scheduled post-dose time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune related features</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>indicated by the percentage of CD8+ T-lymphocytes in peripheral blood at scheduled post-dose time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune related features</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>indicated by the count of natural killer (NK) cells in peripheral blood at scheduled post-dose time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune related features</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>indicated by the percentage of natural killer (NK) cells in peripheral blood at scheduled post-dose time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Percentage of participants with CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Percentage of participants with CR or PR or SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Duration of time of tumor remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Progression-free survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 months overall survival</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>12-month survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable clinical benefit rate at 6 month</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Percentage of participants with CR or PR or SD lasts over six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>The immunogenicity of SHR-1501 single drug and the immunogenicity of SHR-1316 combined with SHR-1501. The indicator includes number of participants with anti-drug antibody positive or neutralizing antibody positive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>SHR-1501 and SHR-1316 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1501 and SHR-1316 dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1501 and SHR-1316 Indication expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1501 given subcutaneously with a recommended dose. SHR-1316 given intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1501</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>SHR-1501 and SHR-1316 Indication expansion</arm_group_label>
    <arm_group_label>SHR-1501 and SHR-1316 dose escalation</arm_group_label>
    <arm_group_label>SHR-1501 and SHR-1316 dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1316</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>SHR-1501 and SHR-1316 Indication expansion</arm_group_label>
    <arm_group_label>SHR-1501 and SHR-1316 dose escalation</arm_group_label>
    <arm_group_label>SHR-1501 and SHR-1316 dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • All Patients All patients must meet all the following criteria to be eligible to
        participate:

          1. Voluntarily participate in this clinical study, understand the research procedure and
             be able to sign informed consent in writing;

          2. Subjects must be willing and able to follow the research protocol;

          3. Aged 18-75 years old when the informed consent form is signed;

          4. Have a histologically or cytologically confirmed diagnosis of advanced or metastatic
             tumor malignancy;

          5. Patients' malignancies must be relapsed or refractory to standard treatment, or
             patients cannot tolerate standard treatment, or patients have actively refused
             standard therapy;

          6. FFPE tumor tissue or unstained slides of tumor sample must be obtained from patients
             enrolled in the dose expansion or indication expansion stage, both preserved samples
             collected within 6 months before the first dose (or up to 12 months prior to the first
             dose) and fresh samples (preferred) are acceptable;

          7. Eastern Cooperative Oncology Group ECOG PS score of 0-1;

          8. Have a life expectancy of ≥ 12 weeks;

          9. Adequate organ function defined according to the protocol, These results should be
             completed within 14 days prior to the first study treatment:

         10. Non-surgically sterilized women of childbearing age or male subjects are required to
             consent to the use of at least one medically approved contraceptive (eg intrauterine
             devices, contraceptives or condoms) is performed during the study treatment period and
             within 3 months of the end of the study treatment period.

        Exclusion Criteria:

          1. Patients with cancerous meningitis (ie meningeal metastasis);

          2. Patients with active central nervous system (CNS) metastasis.

          3. Spinal cord compression that cannot be radically treated with surgery and/or
             radiotherapy cannot be enrolled.

          4. Patients with double cancer or more serious cancer;

          5. Patients with a history of autoimmune diseases;

          6. Significant clinical significance in the history of cardiovascular disease;

          7. Arterial/venous thrombosis events such as cerebrovascular accidents deep vein
             thrombosis and pulmonary embolism within 6 months prior to first administration;

          8. Have a history of immunodeficiency including HIV infection;

          9. Active hepatitis B or hepatitis C patients;

         10. Any disease or symptom that is not appropriate for inclusion in this study determined
             by the investigator.;

         11. Patients have undergone major surgery within 28 days prior to the first dose (except
             for diagnostics);

         12. Those who used a live attenuated vaccine within 4 weeks prior to the first dose or
             expect a live attenuated vaccine during the study period;

         13. Those who received other clinical trials within 4 weeks prior to the first study;

         14. Those who received systemic immunosuppressive therapy within 2 weeks prior to the
             first study dose;

         15. Patients who have previously received allogeneic bone marrow transplantation or solid
             organ transplantation;

         16. A history of severe allergic reactions to other monoclonal antibody/fusion protein
             drugs;

         17. Mental illness, alcohol abuse, drug abuse or substance abuse;

         18. Any disease or condition that causes reasonable suspicion to prohibit the use of the
             study drug or affect the interpretation of the study results or the patient is at high
             risk of treatment complications (any other disease, metabolic disorder, physical
             examination results or laboratory tests abnormalities);

         19. Pregnant or lactating women or women planning to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianjun Zou, MD</last_name>
    <phone>021-68868570</phone>
    <email>zoujianjun@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Shi, MD</last_name>
    <phone>021-68868570</phone>
    <email>shiwei@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sydney Southwest Private Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aflah Roohullah</last_name>
      <phone>87389744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Lemech</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jermaine Coward</last_name>
      <phone>37374500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Flynn Private Hospital</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Tazbirkova</last_name>
      <phone>55314811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yilong Wu, MD</last_name>
      <phone>020-83827812</phone>
      <email>syylwu@live.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

